Crescita Therapeutics acquires INTEGA Skin Sciences

1 September 2016
mergers-acquisitions-big

Canadian topical drug developer Crescita Therapeutics (TSX:CTX) said today that it has acquired INTEGA Skin Sciences, a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skin care products.

The share-based transaction is valued at around $8 million, payable in Crescita common shares valued at $2.44 a share, with a further $2 million payable on the achievement of milestones.

INTEGA, financially backed by Knight Therapeutics (TSX:GUD) and Bloom Burton Healthcare Lending Trust, owns the Canadian distribution rights for a number of well-known and established skin care brands, including Laboratoire Dr Renaud.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...





Today's issue

Company Spotlight